Insider Buying: Opko Health Inc. (OPK) CEO Acquires 5,400 Shares of Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 5,400 shares of the business’s stock in a transaction dated Tuesday, November 22nd. The stock was acquired at an average price of $10.28 per share, for a total transaction of $55,512.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $31,548,816.28. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, November 21st, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The stock was acquired at an average price of $10.41 per share, for a total transaction of $37,476.00.
  • On Friday, November 18th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The stock was acquired at an average price of $10.38 per share, for a total transaction of $18,684.00.
  • On Wednesday, November 16th, Phillip Md Et Al Frost acquired 4,300 shares of Opko Health stock. The stock was acquired at an average price of $10.13 per share, for a total transaction of $43,559.00.
  • On Friday, November 11th, Phillip Md Et Al Frost bought 14,600 shares of Opko Health stock. The stock was purchased at an average price of $9.46 per share, with a total value of $138,116.00.
  • On Wednesday, November 9th, Phillip Md Et Al Frost bought 5,400 shares of Opko Health stock. The stock was purchased at an average price of $9.33 per share, with a total value of $50,382.00.
  • On Tuesday, November 8th, Phillip Md Et Al Frost bought 23,100 shares of Opko Health stock. The stock was purchased at an average price of $9.22 per share, with a total value of $212,982.00.
  • On Wednesday, November 2nd, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The stock was purchased at an average price of $9.48 per share, with a total value of $94,800.00.
  • On Tuesday, November 1st, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The stock was purchased at an average price of $9.49 per share, with a total value of $94,900.00.
  • On Monday, October 31st, Phillip Md Et Al Frost bought 11,800 shares of Opko Health stock. The stock was purchased at an average price of $9.43 per share, with a total value of $111,274.00.
  • On Friday, October 28th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The stock was purchased at an average price of $9.46 per share, with a total value of $94,600.00.

Opko Health Inc. (NASDAQ:OPK) traded down 0.2559% on Wednesday, hitting $10.1739. The stock had a trading volume of 514,953 shares. Opko Health Inc. has a 52-week low of $7.12 and a 52-week high of $11.85. The company has a 50-day moving average price of $9.74 and a 200 day moving average price of $9.86. The firm’s market cap is $5.67 billion.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Monday, November 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). Opko Health had a negative return on equity of 0.49% and a negative net margin of 0.81%. The company had revenue of $298 million for the quarter, compared to analysts’ expectations of $322 million. During the same quarter in the prior year, the firm earned $0.25 earnings per share. Opko Health’s revenue was up 108.4% compared to the same quarter last year. Equities analysts forecast that Opko Health Inc. will post ($0.08) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

A number of research analysts have recently commented on OPK shares. TheStreet cut Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, November 9th. Zacks Investment Research cut Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 19th. Jefferies Group reiterated a “hold” rating on shares of Opko Health in a research note on Wednesday, August 17th. Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of Opko Health in a research note on Monday, October 10th. Finally, JPMorgan Chase & Co. set a $14.00 price objective on Opko Health and gave the company a “buy” rating in a research note on Tuesday, August 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $13.17.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its position in shares of Opko Health by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 947,871 shares of the company’s stock valued at $10,038,000 after buying an additional 28,700 shares during the period. Whalerock Point Partners LLC bought a new stake in shares of Opko Health during the third quarter valued at about $2,100,000. Piedmont Investment Advisors LLC bought a new stake in shares of Opko Health during the third quarter valued at about $622,000. Finally, LPL Financial LLC boosted its stake in shares of Opko Health by 3.9% in the third quarter. LPL Financial LLC now owns 13,374 shares of the company’s stock valued at $142,000 after buying an additional 504 shares during the period. 20.33% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Insider Buying: Opko Health Inc. (OPK) CEO Acquires 5,400 Shares of Stock” was reported by Mideast Time and is the sole property of of Mideast Time. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this news story can be accessed at http://www.mideasttime.com/insider-buying-opko-health-inc-opk-ceo-acquires-5400-shares-of-stock/1418221.html.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NASDAQ:OPK

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2016 Mideast Time.